1. Home
  2. ADPT vs SID Comparison

ADPT vs SID Comparison

Compare ADPT & SID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • SID
  • Stock Information
  • Founded
  • ADPT 2009
  • SID 1941
  • Country
  • ADPT United States
  • SID Brazil
  • Employees
  • ADPT N/A
  • SID N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • SID Steel/Iron Ore
  • Sector
  • ADPT Health Care
  • SID Industrials
  • Exchange
  • ADPT Nasdaq
  • SID Nasdaq
  • Market Cap
  • ADPT 1.8B
  • SID 1.9B
  • IPO Year
  • ADPT 2019
  • SID 1997
  • Fundamental
  • Price
  • ADPT $12.61
  • SID $1.47
  • Analyst Decision
  • ADPT Strong Buy
  • SID Strong Sell
  • Analyst Count
  • ADPT 8
  • SID 1
  • Target Price
  • ADPT $12.38
  • SID $1.30
  • AVG Volume (30 Days)
  • ADPT 1.8M
  • SID 2.2M
  • Earning Date
  • ADPT 11-06-2025
  • SID 11-11-2025
  • Dividend Yield
  • ADPT N/A
  • SID 5.53%
  • EPS Growth
  • ADPT N/A
  • SID N/A
  • EPS
  • ADPT N/A
  • SID N/A
  • Revenue
  • ADPT $205,216,000.00
  • SID $8,202,474,486.00
  • Revenue This Year
  • ADPT $32.76
  • SID $5.24
  • Revenue Next Year
  • ADPT $15.81
  • SID $0.91
  • P/E Ratio
  • ADPT N/A
  • SID N/A
  • Revenue Growth
  • ADPT 21.60
  • SID 2.22
  • 52 Week Low
  • ADPT $3.98
  • SID $1.24
  • 52 Week High
  • ADPT $13.68
  • SID $2.50
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 51.14
  • SID 59.22
  • Support Level
  • ADPT $12.34
  • SID $1.26
  • Resistance Level
  • ADPT $13.68
  • SID $1.52
  • Average True Range (ATR)
  • ADPT 0.56
  • SID 0.05
  • MACD
  • ADPT -0.08
  • SID 0.01
  • Stochastic Oscillator
  • ADPT 20.15
  • SID 73.68

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About SID Companhia Siderurgica Nacional S.A.

Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.

Share on Social Networks: